Single-cell RNA-seq enables comprehensive tumour and immune cell profiling in primary breast cancer

Nature Communications

Volumn 8, Issue , 2017, Pages

  Chung, Woosung ^a,b   Eum, Hye Hyeon ^a,c   Lee, Hae Ock ^a,b   Lee, Kyung Min ^d,e   Lee, Han Byoel ^c,d   Kim, Kyu Tae ^a   Ryu, Han Suk ^c   Kim, Sangmin ^f   Lee, Jeong Eon ^f   Park, Yeon Hee ^a   Kan, Zhengyan ^g   Han, Wonshik ^c,d   Park, Woong Yang ^a,b  

^a Samsung Medical Center   (South Korea)

^b Sungkyunkwan University   (South Korea)

^c Seoul National University   (South Korea)

^d Seoul National University College of Medicine   (South Korea)

^e Seoul National University Hospital   (South Korea)

^f Sungkyunkwan University School of Medicine   (South Korea)

^g PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSCRIPTOME; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

CANCER; CELLS AND CELL COMPONENTS; GENETIC ANALYSIS; HETEROGENEITY; PHENOTYPE; RNA; TUMOR;

ARTICLE; B LYMPHOCYTE; BREAST CANCER; BREAST CANCER CELL LINE; CLINICAL ARTICLE; CONTROLLED STUDY; COPY NUMBER VARIATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCOMPETENT CELL; MACROPHAGE; PHENOTYPE; PRIMARY BREAST CANCER; RNA SEQUENCE; SINGLE CELL ANALYSIS; T LYMPHOCYTE; TUMOR MICROENVIRONMENT; BREAST TUMOR; FEMALE; GENE EXPRESSION PROFILING; GENETICS; IMMUNOLOGY; LYMPH NODE; METABOLISM; PAGET NIPPLE DISEASE; PATHOLOGY; PROCEDURES; SEQUENCE ANALYSIS; TRIPLE NEGATIVE BREAST CANCER; TUMOR ASSOCIATED LEUKOCYTE; WHOLE EXOME SEQUENCING;

B-LYMPHOCYTES; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; DNA COPY NUMBER VARIATIONS; FEMALE; GENE EXPRESSION PROFILING; HUMANS; LYMPH NODES; LYMPHOCYTES, TUMOR-INFILTRATING; MACROPHAGES; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SEQUENCE ANALYSIS, RNA; SINGLE-CELL ANALYSIS; T-LYMPHOCYTES; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR MICROENVIRONMENT; WHOLE EXOME SEQUENCING;

EID: 85018370681     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms15081     Document Type: Article

References (60)

1. Harvey, J. M., Clark, G. M., Osborne, C. K. & Allred, D. C. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J. Clin. Oncol. 17, 1474-1481 (1999).
2. Higgins, M. J. & Baselga, J. Targeted therapies for breast cancer. J. Clin. Invest. 121, 3797-3803 (2011).
3. Cardoso, F. et al. Clinical application of the 70-gene profile: the MINDACT trial. J. Clin. Oncol. 26, 729-735 (2008).
4. Sparano, J. A. & Paik, S. Development of the 21-gene assay and its application in clinical practice and clinical trials. J. Clin. Oncol. 26, 721-728 (2008).
5. Wang, Y. et al. Clonal evolution in breast cancer revealed by single nucleus genome sequencing. Nature 512, 155-160 (2014).
6. Ng, C. K. et al. Intra-tumor genetic heterogeneity and alternative driver genetic alterations in breast cancers with heterogeneous HER2 gene amplification. Genome Biol. 16, 107 (2015).
7. Osborne, C. K. & Schiff, R. Mechanisms of endocrine resistance in breast cancer. Annu. Rev. Med. 62, 233-247 (2011).
8. Finak, G. et al. Stromal gene expression predicts clinical outcome in breast cancer. Nat. Med. 14, 518-527 (2008).
9. Salgado, R. et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann. Oncol. 26, 259-271 (2015).
10. Galon, J. et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313, 1960-1964 (2006).
11. Erez, N., Truitt, M., Olson, P., Arron, S. T. & Hanahan, D. Cancer-associated fibroblasts are activated in incipient neoplasia to orchestrate tumor-promoting inflammation in an NF-kappaB-dependent manner. Cancer Cell 17, 135-147 (2010).
12. Gajewski, T. F., Schreiber, H. & Fu, Y. X. Innate and adaptive immune cells in the tumor microenvironment. Nat. Immunol. 14, 1014-1022 (2013).
13. Luo, Y. et al. Targeting tumor-associated macrophages as a novel strategy against breast cancer. J. Clin. Invest. 116, 2132-2141 (2006).
14. Schwartz, M., Zhang, Y. & Rosenblatt, J. D. B cell regulation of the anti-tumor response and role in carcinogenesis. J. Immunother. Cancer 4, 40 (2016).
15. Mahmoud, S. M. et al. The prognostic significance of B lymphocytes in invasive carcinoma of the breast. Breast Cancer Res. Treat. 132, 545-553 (2012).
16. Navin, N. E. The first five years of single-cell cancer genomics and beyond. Genome Res. 25, 1499-1507 (2015).
17. Kim, K. T. et al. Single-cell mRNA sequencing identifies subclonal heterogeneity in anti-cancer drug responses of lung adenocarcinoma cells. Genome Biol. 16, 127 (2015).
18. Navin, N. E. Delineating cancer evolution with single-cell sequencing. Sci. Transl. Med. 7, 296fs229 (2015).
19. Hu, X. et al. Genetic alterations and oncogenic pathways associated with breast cancer subtypes. Mol. Cancer Res. 7, 511-522 (2009).
20. Cancer Genome Atlas N. Comprehensive molecular portraits of human breast tumours. Nature 490, 61-70 (2012).
21. Banerji, S. et al. Sequence analysis of mutations and translocations across breast cancer subtypes. Nature 486, 405-409 (2012).
22. Curtis, C. et al. The genomic and transcriptomic architecture of 2, 000 breast tumours reveals novel subgroups. Nature 486, 346-352 (2012).
23. Wu, A. R. et al. Quantitative assessment of single-cell RNA-sequencing methods. Nat. Methods 11, 41-46 (2014).
24. Patel, A. P. et al. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science 344, 1396-1401 (2014).
25. Pollack, J. R. et al. Genome-wide analysis of DNA copy-number changes using cDNA microarrays. Nat. Genet. 23, 41-46 (1999).
26. Yoshihara, K. et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat. Commun. 4, 2612 (2013).
27. Desmedt, C. et al. Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin. Cancer Res. 14, 5158-5165 (2008).
28. Wirapati, P. et al. Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res. 10, R65 (2008).
29. Lawson, D. A. et al. Single-cell analysis reveals a stem-cell program in human metastatic breast cancer cells. Nature 526, 131-135 (2015).
30. Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545-15550 (2005).
31. Fumagalli, D. et al. Transfer of clinically relevant gene expression signatures in breast cancer: from Affymetrix microarray to Illumina RNA-Sequencing technology. BMC Genomics 15, 1008 (2014).
32. Macosko, E. Z. et al. Highly parallel genome-wide expression profiling of individual cells using nanoliter droplets. Cell 161, 1202-1214 (2015).
33. Gruvberger, S. et al. Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns. Cancer Res. 61, 5979-5984 (2001).
34. Prall, O. W., Rogan, E. M., Musgrove, E. A., Watts, C. K. & Sutherland, R. L. c-Myc or cyclin D1 mimics estrogen effects on cyclin E-Cdk2 activation and cell cycle reentry. Mol. Cell Biol. 18, 4499-4508 (1998).
35. Rakha, E. A. et al. Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes. Clin. Cancer Res. 15, 2302-2310 (2009).
36. Lehmann, B. D. et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J. Clin. Invest. 121, 2750-2767 (2011).
37. Bindea, G. et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity 39, 782-795 (2013).
38. Klein, U. et al. Transcriptional analysis of the B cell germinal center reaction. Proc. Natl Acad. Sci. USA 100, 2639-2644 (2003).
39. Tirosh, I. et al. Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Science 352, 189-196 (2016).
40. Jiang, Y., Li, Y. & Zhu, B. T-cell exhaustion in the tumor microenvironment. Cell Death Dis. 6, e1792 (2015).
41. Pfoertner, S. et al. Signatures of human regulatory T cells: an encounter with old friends and new players. Genome Biol. 7, R54 (2006).
42. Postow, M. A., Callahan, M. K. & Wolchok, J. D. Immune checkpoint blockade in cancer therapy. J. Clin. Oncol. 33, 1974-1982 (2015).
43. Fuertes Marraco, S. A., Neubert, N. J., Verdeil, G. & Speiser, D. E. Inhibitory receptors beyond T cell exhaustion. Front. Immunol. 6, 310 (2015).
44. Noy, R. & Pollard, J. W. Tumor-associated macrophages: from mechanisms to therapy. Immunity 41, 49-61 (2014).
45. Martinez, F. O., Gordon, S., Locati, M. & Mantovani, A. Transcriptional profiling of the human monocyte-to-macrophage differentiation and polarization: new molecules and patterns of gene expression. J. Immunol. 177, 7303-7311 (2006).
46. Singh, J. K., Simoes, B. M., Howell, S. J., Farnie, G. & Clarke, R. B. Recent advances reveal IL-8 signaling as a potential key to targeting breast cancer stem cells. Breast Cancer Res. 15, 210 (2013).
47. Nguyen, L. T. & Ohashi, P. S. Clinical blockade of PD1 and LAG3-potential mechanisms of action. Nat. Rev. Immunol. 15, 45-56 (2015).
48. Johnston, R. J. et al. The immunoreceptor TIGIT regulates antitumor and antiviral CD8 T cell effector function. Cancer Cell 26, 923-937 (2014).
49. Lee, J. H. et al. Fluorescent in situ sequencing (FISSEQ) of RNA for gene expression profiling in intact cells and tissues. Nat. Protoc. 10, 442-458 (2015).
50. Haibe-Kains, B. et al. A three-gene model to robustly identify breast cancer molecular subtypes. J. Natl Cancer Inst. 104, 311-325 (2012).
51. Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25, 1754-1760 (2009).
52. DePristo, M. A. et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat. Genet. 43, 491-498 (2011).
53. Cibulskis, K. et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat. Biotechnol. 31, 213-219 (2013).
54. Boeva, V. et al. Control-FREEC: a tool for assessing copy number and allelic content using next-generation sequencing data. Bioinformatics 28, 423-425 (2012).
55. Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15-21 (2013).
56. Li, B. & Dewey, C. N. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinformatics 12, 323 (2011).
57. DeLuca, D. S. et al. RNA-SeQC: RNA-seq metrics for quality control and process optimization. Bioinformatics 28, 1530-1532 (2012).
58. Hanzelmann, S., Castelo, R. & Guinney, J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics 14, 7 (2013).
59. Chen, X. et al. TNBCtype: a subtyping tool for triple-negative breast cancer. Cancer Inform. 11, 147-156 (2012).
60. Gaujoux, R. & Seoighe, C. A flexible R package for nonnegative matrix factorization. BMC Bioinformatics 11, 367 (2010).